Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- Mar 17
- 1 min read
17/03/2026
Celltrion announced that the tocilizumab SC formulation was now commercially available to patients in the US (Ref)
Celltrion announced that AVTOZMA® (tocilizumab; IL-6 receptor antagonist) subcutaneous (SC) formulation was now commercially available to patients in the United States
AVTOZMA® was among the first wave of tocilizumab biosimilars with both intravenous (IV) and subcutaneous (SC) formulations approved and commercially available in the United States
The SC formulation of AVTOZMA® was indicated for the treatment of rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (PJIA) and systemic juvenile idiopathic arthritis (SJIA)
